DPDP Compliance for Genetic & DNA Testing Data
Liability Check
Processing genetic and DNA testing data is an ultra-high-risk activity under the DPDP Act. Mismanagement of this highly sensitive personal data can attract penalties even higher than the ₹250 Crore cap, with potential for ongoing fines for each individual affected.
Why DPDP Compliance for Genetic & DNA Testing Data is at Risk
Genetic and DNA data is uniquely sensitive because it reveals immutable personal information, predispositions, and can even identify family members. The DPDP Act considers this **'special category personal data'**, requiring a higher standard of consent and security. Companies like GenomeLink or GeneHealth India operating from tech parks in Bengaluru or Hyderabad need to ensure their data processing practices are watertight, including **anonymisation**, **encryption**, and strict access controls. Without explicit, purpose-specific consent, using this data for research, marketing, or even internal analysis is a **grave violation**. The potential for misuse, discrimination, and re-identification is immense, making this a top priority for the Data Protection Board.
Common Violations
- 1.Using **genetic data** for research or marketing without specific, explicit consent for *each* separate purpose.
- 2.Storing unencrypted **DNA sequence data** or failing to implement robust, granular access controls for genetic databases.
- 3.Sharing **genetic test results** with third-party labs, insurance providers, or research institutions without separate, auditable consent from the Data Principal.
The Immediate Fix
Immediately conduct a **data mapping exercise** to identify all genetic and DNA data you process, where it's stored, and who has access. Then, audit your consent acquisition process to ensure it's **explicit, purpose-specific, and auditable** for every data principal. Prioritize **end-to-end encryption** for all genetic data at rest and in transit.
Projected Compliance Deadline: Immediate